HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Medications are the first-line treatment for atrial fibrillation, or A-fib. When they begin to fail, one option is ablation.

Please provide your email address to receive an email when new articles are posted on . A novel SK ion channel inhibitor more often converted atrial fibrillation to sinus rhythm compared with placebo.

A research group led by Assistant Professor Megumi Aimoto and Professor Akira Takahara at the Faculty of Pharmaceutical Sciences, Toho University, revealed that pyrazole-3 (Pyr3), a selective ...

A new study by researchers at the University of Arizona College of Medicine – Phoenix and the University of California Davis Health identified a new target for developing a therapy to treat atrial ...

Despite being the most common form of cardiac arrhythmia, atrial fibrillation (AFib) is a condition that often goes undiagnosed and/or untreated. The condition, which often accompanies other health ...

A brand new procedure to treat atrial fibrillation is now being offered at several hospitals across Colorado after UCHealth in Loveland successfully completed the first procedure in the state. c "Afib ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers ...